DR info

臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

111JC101
   Biogen Idec Ltd
      2009   -   EUCTR2008-001314-24-GB   France;Italy;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-001314-24-FR   France;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001314-24-ES   France;Italy;Spain;United Kingdom;
CYT107
   CYTHERIS
      2012   -   EUCTR2012-000725-41-IT   Italy;Spain;Switzerland;United Kingdom;United States;
   Cytheris S.A.
      2013   -   EUCTR2012-000725-41-GB   European Union;Italy;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2012-000725-41-ES   European Union;Spain;Switzerland;United Kingdom;United States;
Cidofovir
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   -   NCT00000945   United States;
Collection of blood and urine
   University Hospital, Toulouse
      2021   -   NCT04453917   France;
Cytarabine
   National Institute of Allergy and Infectious Diseases (NIAID)
      1998   Phase 2   NCT00001048   United States;
Didanosine
   Bristol-Myers Squibb
      1997   -   NCT00002274   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      1998   Phase 2   NCT00001048   United States;
Enfuvirtide
   French National Agency for Research on AIDS and Viral Hepatitis
      2005   Phase 2   NCT00120367   France;
Filgrastim
   National Institute of Allergy and Infectious Diseases (NIAID)
      1998   Phase 2   NCT00001048   United States;
Interferon alfa-2b
   University of Miami
      1997   -   NCT00002270   United States;
Lariam
   BIOGEN IDEC LTD
      2009   -   EUCTR2008-001314-24-IT   France;Italy;Spain;United Kingdom;
   Biogen Idec Ltd
      2009   -   EUCTR2008-001314-24-GB   France;Italy;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-001314-24-FR   France;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001314-24-ES   France;Italy;Spain;United Kingdom;
Mefloquine
   BIOGEN IDEC LTD
      2009   -   EUCTR2008-001314-24-IT   France;Italy;Spain;United Kingdom;
   Biogen
      2009   Phase 1/Phase 2   NCT00746941   Australia;Brazil;France;Germany;Italy;Puerto Rico;Spain;United Kingdom;United States;
   Department of Neurology, Shimane University Hospital
      2016   -   JPRN-UMIN000022151   Japan;
   Nagoya City University
      2016   -   JPRN-UMIN000023752   Japan;
Methylprednisolone
   Biogen
      2010   Phase 4   NCT01211665   Germany;United States;
NT-I7
   National Institute of Neurological Disorders and Stroke (NINDS)
      2021   Early Phase 1   NCT04781309   United States;
Natalizumab
   Biogen
      2019   -   NCT05236777   Czechia;
Neurological evaluation
   University Hospital, Toulouse
      2021   -   NCT04453917   France;
Pembrolizumab
   First Affiliated Hospital of Zhejiang University
      2019   Phase 2   NCT04091932   China;
Prednisolone
   Biogen
      2010   Phase 4   NCT01211665   Germany;United States;
Probenecid
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   -   NCT00000945   United States;
PyVST
   National Institute of Neurological Disorders and Stroke (NINDS)
      2016   Early Phase 1   NCT02694783   United States;
Recombinant human interleukin-7
   CYTHERIS
      2012   -   EUCTR2012-000725-41-IT   Italy;Spain;Switzerland;United Kingdom;United States;
   Cytheris S.A.
      2013   -   EUCTR2012-000725-41-GB   European Union;Italy;Spain;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2012-000725-41-ES   European Union;Spain;Switzerland;United Kingdom;United States;
Spinal tap
   University Hospital, Toulouse
      2021   -   NCT04453917   France;
Tenofovir-Emtricitabine
   French National Agency for Research on AIDS and Viral Hepatitis
      2005   Phase 2   NCT00120367   France;
Teriflunomide
   Providence Health & Services
      2013   Phase 4   NCT01970410   United States;
Topotecan
   SmithKline Beecham
      1996   Phase 2   NCT00002395   United States;
Tysabri
   Biogen
      2018   -   NCT03399981   United States;
Zalcitabine
   National Institute of Allergy and Infectious Diseases (NIAID)
      1998   Phase 2   NCT00001048   United States;
Zidovudine
   National Institute of Allergy and Infectious Diseases (NIAID)
      1998   Phase 2   NCT00001048   United States;
   University of Miami
      1997   -   NCT00002270   United States;